Having trouble accessing articles? Reset your cache.

Can-Fite's CF101 meets in Phase IIb RA trial

Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF) said twice-daily oral CF101 met the primary endpoint of improving ACR20

Read the full 175 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE